Epigenomics AG announces changes in its Executive Management Board
Advertisement
The Supervisory Board of Epigenomics AG and its current CEO Geert Walter Nygaard agreed that Mr. Nygaard will leave the Executive Management Board of the company effective 30 September 2012.
The current CFO, Dr. Thomas Taapken, thereby becomes the sole Executive Board member of the company and this capacity also takes over the responsibility of acting CEO of Epigenomics, effective 1 October 2012. Dr. Uwe Staub, currently SVP R&D was promoted to COO and was granted “Prokura” (power of attorney). His duties will be expanded by the responsibility for medical affairs and customer support.